Ex-Glaxo Official Sues Over Firing Tied to Study Mistakes
The London-based drugmaker’s refusal to acknowledge statistical flaws in the Nicoderm studies allowed Glaxo to illegally market the quit-smoking aides as more effective than rival products, Selmani said in his complaint, filed Jan. 6 in state court in New Jersey.